34 results on '"Giobbie-Hurder, Anita"'
Search Results
2. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
3. A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma
4. A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
5. Targeting TBK1 to overcome resistance to cancer immunotherapy
6. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
7. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
8. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery
9. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
10. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
11. Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial
12. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations
13. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors
14. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
15. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
16. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
17. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
18. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
19. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
20. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
21. Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma
22. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
23. Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade
24. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
25. Erratum: Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma
26. An immunogenic personal neoantigen vaccine for patients with melanoma
27. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
28. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes
29. A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome
30. Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
31. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
32. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial
33. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors
34. Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.